XBIT - XBiotech Inc logo

XBiotech Inc

XBIT

XBiotech Inc. develops True Human monoclonal antibodies for treating diseases. Its pipeline focuses on therapies for inflammatory and infectious diseases, including cancer, stroke, and arthritis, addressing tissue breakdown, angiogenesis, and general inflammation.

⚕️ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 10 years ago →$148today

Score Overview

1 Year
Score—
Net Growth11.81%
Net TrendGrew
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
Score2.1
Net Growth-130.62%
Net Trend40%
Net Income Consistency—
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency—
10 Years
Score—
Net Growth23.88%
Net Trend50%
Net Income Consistency
Rev Growth—
Rev Trend20%
Revenue Consistency
All Time
Score—
Net Growth-7.14%
Net Trend45%
Net Income Consistency
Rev Growth—
Rev Trend18%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where XBiotech Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. XBIT does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-21
$ 1.99—
1 Year2025-10-21
$ 2.59-23.17%
5 Years2021-10-21
$ 13.99-85.78%
10 Years2016-10-21
$ 13.45-85.20%
All Time2015-04-15
$ 20.03-90.07%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 40M$ 115M
2025$ 0.00-$ 45M$ 125M
2024$ 0.00-$ 38M$ 172M
2023$ 300K-$ 24M$ 200M
2022$ 4M-$ 32M$ 217M
2021$ 18M-$ 17M$ 236M
2020$ 43M-$ 11M$ 237M
2019$ 12M$ 668M$ 714M
2018$ 0.00-$ 21M$ 15M
2017$ 0.00-$ 33M$ 31M
2016$ 0.00-$ 52M$ 34M
IPO2015$ 0.00-$ 37M$ 91M
XBIT - XBiotech Inc logo

XBiotech Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 43M to $ 0.00 and net income went from -$ 11M to -$ 45M. Revenue increased in 0 of those 5 years; net income in 2.

XBiotech Inc currently holds a 5-year HDB Score of 2.1 out of 10. How the HDB Score is calculated.

Membership

Explore XBIT with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,118 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies